Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Inclusion Criteria: * Histologically or cytologically confirmed unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma; * Patients failed first-line chemotherapy containing fluoropyrimidines and platinums; * ECOG (Eastern Cooperative Oncology Group)performance status 0-1; * At least 1 measurable lesion should be present（RECIST1.1） * Available Organ function: Neutrophils\>2g/L, Hemoglobin\>9g/L, Blood platelet \>100g/L; Alanine aminotransferase(ALT） and Aspartate aminotransferase(AST)\<1.5 ULN(upper limit of normal); Total bilirubin(TBIL)\<1.0 ULN; Cr \<1.0ULN * Signed informed consent. * Life expectancy ≥3 months; Exclusion Criteria: * Previous treatment with Raltitrexed or Paclitaxel; * Known history of allergic reaction to Raltitrexed or Paclitaxel; * Known brain metastases; * Pregnant or breast feeding women; * Severe diarrhea,intestinal obstruction; * other co-existing malignancies or malignancies diagnosed within the last 5 years(except cured cutaneum carcinoma or carcinoma in situs of cervix); * Previous myocardial infarction, unstable angina, stroke ,or uncontrollable Arrhythmia; * Kown HIV infecton.